Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - November 2014


Advances in Cell Based Assays

11 Nov 2014 - 12 Nov 2014 - London, UK



Bookmark and Share


SMi Group invites you to attend the market leading cell based event, Advances in Cell Based Assays, taking place on 11th & 12th November in Central London.

We have worked closely with an array of industry KOLs and scientific leaders to host a packed conference agenda for the 7th annual conference this autumn

Expand your scientific horizons as we ask the questions: 

  • How have recent advances in high throughput sample expression techniques opened up new possibilities for primary HTS within the biologics industry? 
  • What are the current challenges of bioassay method development and how can we validate these with reference to cell based assays and regulatory guidelines in drug development? 
  • What is the next generation of target identification and screening technologies? 
  • How easy is it to use adult stem cells in therapeutic applications, in vitro and in vivo paradigm?
  • How can we exploit gene editing in human cell lines to provide novel, isogenic assays? 
  • How are new technologies impacting the industry? 
  • 3D cell culture, how can this be used in oncology research? 
  • What is the next generation of cell based assays?

Key Speakers Include:

  • Steve Ludbrook, Group Leader, Biological Sciences UK, RD Platform Technology & Science, GSK
  • Beverley Isherwood, Team Leader High Content Biology, Innovative Medicines, AstraZeneca R&D
  • Dr Lesley Jenkinson, Scientist 1, Medimmune
  • Dr Farnaz Fallah-Arani, Group Leader, Pharmacology, UCB
  • Neil Carragher, PhD, Principal Investigator Drug Discovery, Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh
  • Niclas Nilsson, Head of Section, Lead Discovery, LEO Pharma
  • Dr Christa Burger, Principal Scientist, Cellular Pharmacology, Merck Serono
  • Dr Marianne Uteng, PhD, Head of Cellular Models & HCB Laboratory, Discovery and Investigative Safety (DIS), Novartis
  • Anker Jon Hansen, Principal Scientist, Novo Nordisk
  • Daniel Nolan, Director of Research, Angiocrine Bioscience

For further details and to download a copy of the PDF,  visit http://www.smi-online.co.uk/goto/2014cellbasedassay36.asp 

Alternatively contact Fateja Begum on +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk



Further information
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!